Athena Heart 310 🎯 Popular

Detailed clinical summaries and press releases are available directly from CRISPR Therapeutics and medical news sources like Drug Discovery News . If you'd like to dive deeper into the research:

Recent data from clinical studies, including updates as of late 2025, show significant efficacy in participants: ATHENA HEART 310

Targeted protein levels decreased by an average of 73%. Detailed clinical summaries and press releases are available

ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. By "turning off" this gene, the body can

(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1)

Mean reductions of ~49%, with peak effects reaching 87% .